Clinical Research & News
Dr. Rubin's commitment to advancing pain medicine through active research participation.
Dr. Edward Rubin is an active participant in FDA clinical research — bringing cutting-edge treatments to Long Island patients before they reach widespread availability. His current involvement includes a Phase 2 multicenter trial for Halneuron, a novel therapy for chemotherapy-induced neuropathic pain. His commitment to research ensures that his patients have access to the most advanced and evidence-supported therapies available.
Active Clinical Trial
Halneuron for Chemotherapy-Induced Neuropathic Pain (CINP)
RecruitingA randomized, double-blind, placebo-controlled multicenter study evaluating the efficacy and safety of a single subcutaneous administration of Halneuron (HAL) in patients with neuropathic pain caused by platinum and/or taxane chemotherapy. Dr. Rubin is a participating investigator. Eligible patients must be ≥18 years old with confirmed CINP attributed to prior platinum or taxane chemotherapy, with no active disease progression.
View on ClinicalTrials.govInterested in Clinical Trial Participation?
If you have a condition that may qualify for one of Dr. Rubin's active research protocols, contact our office to discuss eligibility.
Contact Us